Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2012 /
Development of future cancer treatments

4th - 7th Nov 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.11.12
Views: 2796
Rating:

Dr Herbie Newell - Northern Institute for Cancer Research, Newcastle, UK

Dr Herbie Newell discusses the development of cancer treatments and the role that partnerships between academia and the pharmaceutical industry have to play in this process.

 

Dr Newell explains how the appropriate use of biomarkers could decrease the time taken to bring a new treatment to market, outlines the drug targets that he expects to be important in future cancer treatment and considers the role that the MDM-p53 signalling pathway could play in the development of epigenetic drug targets. 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation